Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985824393> ?p ?o ?g. }
- W2985824393 endingPage "80" @default.
- W2985824393 startingPage "70" @default.
- W2985824393 abstract "Abstract Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine. Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger trials; consequently, many questions remain as to the optimal vaccine formulation, predictive biomarkers, and sequencing and timing of vaccines in melanoma treatment. We conducted an adjuvant phase I/II clinical trial in high-risk resected melanoma to optimize the delivery of poly-ICLC, a TLR-3/MDA-5 agonist, as a component of vaccine formulation. A phase I dose-escalation part was undertaken to identify the MTD of poly-ICLC administered in combination with NY-ESO-1 and montanide. This was followed by a randomized phase II part investigating the MTD of poly-ICLC with NY-ESO-1 with or without montanide. The vaccine regimens were generally well tolerated, with no treatment-related grade 3/4 adverse events. Both regimens induced integrated NY-ESO-1–specific CD4+ T-cell and humoral responses. CD8+ T-cell responses were mainly detected in patients receiving montanide. T-cell avidity toward NY-ESO-1 peptides was higher in patients vaccinated with montanide. In conclusion, NY-ESO-1 protein in combination with poly-ICLC is safe, well tolerated, and capable of inducing integrated antibody and CD4+ T-cell responses in most patients. Combination with montanide enhances antigen-specific T-cell avidity and CD8+ T-cell cross-priming in a fraction of patients, indicating that montanide contributes to the induction of specific CD8+ T-cell responses to NY-ESO-1." @default.
- W2985824393 created "2019-11-22" @default.
- W2985824393 creator A5001245704 @default.
- W2985824393 creator A5003290165 @default.
- W2985824393 creator A5022765571 @default.
- W2985824393 creator A5031532689 @default.
- W2985824393 creator A5041066193 @default.
- W2985824393 creator A5048724240 @default.
- W2985824393 creator A5054194432 @default.
- W2985824393 creator A5054903510 @default.
- W2985824393 creator A5055358847 @default.
- W2985824393 creator A5056507476 @default.
- W2985824393 creator A5057343975 @default.
- W2985824393 creator A5076789267 @default.
- W2985824393 creator A5078046623 @default.
- W2985824393 creator A5089244576 @default.
- W2985824393 creator A5091736003 @default.
- W2985824393 date "2020-01-01" @default.
- W2985824393 modified "2023-10-12" @default.
- W2985824393 title "Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma" @default.
- W2985824393 cites W1488583473 @default.
- W2985824393 cites W1944300754 @default.
- W2985824393 cites W1970087181 @default.
- W2985824393 cites W1970297719 @default.
- W2985824393 cites W1985496335 @default.
- W2985824393 cites W1988321780 @default.
- W2985824393 cites W2009052042 @default.
- W2985824393 cites W2038632547 @default.
- W2985824393 cites W2038820219 @default.
- W2985824393 cites W2055724916 @default.
- W2985824393 cites W2057416573 @default.
- W2985824393 cites W2060070314 @default.
- W2985824393 cites W2063366670 @default.
- W2985824393 cites W2070825440 @default.
- W2985824393 cites W2071244674 @default.
- W2985824393 cites W2071670416 @default.
- W2985824393 cites W2074120439 @default.
- W2985824393 cites W2076956606 @default.
- W2985824393 cites W2088139924 @default.
- W2985824393 cites W2096109794 @default.
- W2985824393 cites W2096614211 @default.
- W2985824393 cites W2097575786 @default.
- W2985824393 cites W2097995306 @default.
- W2985824393 cites W2099560139 @default.
- W2985824393 cites W2100143031 @default.
- W2985824393 cites W2104525960 @default.
- W2985824393 cites W2110632746 @default.
- W2985824393 cites W2117914559 @default.
- W2985824393 cites W2128758225 @default.
- W2985824393 cites W2138651252 @default.
- W2985824393 cites W2139029604 @default.
- W2985824393 cites W2142151289 @default.
- W2985824393 cites W2143935255 @default.
- W2985824393 cites W2147557533 @default.
- W2985824393 cites W2150835657 @default.
- W2985824393 cites W2152897456 @default.
- W2985824393 cites W2153712501 @default.
- W2985824393 cites W2168530155 @default.
- W2985824393 cites W2174267452 @default.
- W2985824393 cites W2587048937 @default.
- W2985824393 cites W2604830835 @default.
- W2985824393 cites W2752227448 @default.
- W2985824393 cites W2789167832 @default.
- W2985824393 cites W2797309423 @default.
- W2985824393 cites W2800706673 @default.
- W2985824393 cites W2892876553 @default.
- W2985824393 doi "https://doi.org/10.1158/2326-6066.cir-19-0545" @default.
- W2985824393 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6946846" @default.
- W2985824393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31699709" @default.
- W2985824393 hasPublicationYear "2020" @default.
- W2985824393 type Work @default.
- W2985824393 sameAs 2985824393 @default.
- W2985824393 citedByCount "42" @default.
- W2985824393 countsByYear W29858243932020 @default.
- W2985824393 countsByYear W29858243932021 @default.
- W2985824393 countsByYear W29858243932022 @default.
- W2985824393 countsByYear W29858243932023 @default.
- W2985824393 crossrefType "journal-article" @default.
- W2985824393 hasAuthorship W2985824393A5001245704 @default.
- W2985824393 hasAuthorship W2985824393A5003290165 @default.
- W2985824393 hasAuthorship W2985824393A5022765571 @default.
- W2985824393 hasAuthorship W2985824393A5031532689 @default.
- W2985824393 hasAuthorship W2985824393A5041066193 @default.
- W2985824393 hasAuthorship W2985824393A5048724240 @default.
- W2985824393 hasAuthorship W2985824393A5054194432 @default.
- W2985824393 hasAuthorship W2985824393A5054903510 @default.
- W2985824393 hasAuthorship W2985824393A5055358847 @default.
- W2985824393 hasAuthorship W2985824393A5056507476 @default.
- W2985824393 hasAuthorship W2985824393A5057343975 @default.
- W2985824393 hasAuthorship W2985824393A5076789267 @default.
- W2985824393 hasAuthorship W2985824393A5078046623 @default.
- W2985824393 hasAuthorship W2985824393A5089244576 @default.
- W2985824393 hasAuthorship W2985824393A5091736003 @default.
- W2985824393 hasBestOaLocation W29858243932 @default.
- W2985824393 hasConcept C147483822 @default.
- W2985824393 hasConcept C159654299 @default.
- W2985824393 hasConcept C167672396 @default.
- W2985824393 hasConcept C179223381 @default.